531210 COLINZ

Colinz Laboratories Share Price

 

 

Start SIP in COLINZ

Start SIP

Performance

  • Low
  • ₹54
  • High
  • ₹57
  • 52 Week Low
  • ₹36
  • 52 Week High
  • ₹89
  • Open Price₹57
  • Previous Close₹57
  • Volume884
  • 50 DMA₹55.48
  • 100 DMA₹51.33
  • 200 DMA₹50.16

Investment Returns

  • Over 1 Month + 0.72%
  • Over 3 Month + 36.97%
  • Over 6 Month + 23.91%
  • Over 1 Year + 0.85%

Smart Investing Starts Here Start SIP with Colinz Laboratories for Steady Growth!

Invest Now

Colinz Laboratories Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 27.8
  • PEG Ratio
  • 11.7
  • Market Cap Cr
  • 14
  • P/B Ratio
  • 1.4
  • Average True Range
  • 5.51
  • EPS
  • -
  • Dividend Yield
  • 0
  • MACD Signal
  • 4.4
  • RSI
  • 43.86
  • MFI
  • 91.66

Colinz Laboratories Financials

Colinz Laboratories Technicals

EMA & SMA

Current Price
₹54.46
-2.86 (-4.99%)
pointer
  • Bearish Moving Average 10
  • Bullish Moving Average 6
  • 20 Day
  • ₹61.25
  • 50 Day
  • ₹55.48
  • 100 Day
  • ₹51.33
  • 200 Day
  • ₹50.16

Resistance and Support

55.41 Pivot Speed
  • R3 59.23
  • R2 58.27
  • R1 56.37
  • S1 53.51
  • S2 52.55
  • S3 50.65

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Colinz Laboratories has an operating revenue of Rs. 5.84 Cr. on a trailing 12-month basis. An annual revenue de-growth of -6% needs improvement, Pre-tax margin of 9% is okay, ROE of 5% is fair but needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. From an O'Neil Methodology perspective, the stock has an EPS Rank of 67 which is a FAIR score but needs to improve its earnings, a RS Rating of 87 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 74 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of B is close to being the best. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail. Please note that this is a thinly traded stock.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Colinz Laboratories Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-01-24 Quarterly Results
2026-01-17 Others
2025-11-27 Others Inter-alia to approve appointment of Ms. Falguni Kumawat as the Company Secretary and Compliance Officer of the Company and Key Managerial Personnel of the Company.
2025-11-11 Others Inter-alia, to approve appointment of Smt. Vijaya Mani (DIN 11363910) as Additional (Non- Executive) Director of the Company.
2025-11-03 Quarterly Results

Colinz Laboratories F&O

Colinz Laboratories Shareholding Pattern

66%
31.01%
2.99%

Colinz Laboratories FAQs

Colinz Laboratories share price is ₹54 As on 12 February, 2026 | 04:23

The Market Cap of Colinz Laboratories is ₹13.7 Cr As on 12 February, 2026 | 04:23

The P/E ratio of Colinz Laboratories is 27.8 As on 12 February, 2026 | 04:23

The PB ratio of Colinz Laboratories is 1.4 As on 12 February, 2026 | 04:23

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23